- Market Capitalization, $K 73,587,752
- Shares Outstanding, K 2,047,517
- Annual Sales, $ 36,271 M
- Annual Income, $ 18,499 M
- 60-Month Beta 0.64
- Price/Sales 2.03
- Price/Cash Flow 8.11
- Price/Book 4.64
|Period||Period Low||Period High||Performance|
| || |
+0.88 (+2.51%)since 11/08/23
| || |
-0.61 (-1.67%)since 09/08/23
| || |
-0.66 (-1.80%)since 12/08/22
The pharmaceutical industry is well-positioned for robust growth, driven by growing healthcare expenditure globally and the rapid adoption of digital technologies. Given the industry’s tailwinds, fundamentally...
Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach...
The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological...
The world is a big place, and many great companies are based outside our U.S. borders.
Amid the burgeoning technological innovation and its seamless integration, investors' interest seems to gravitate toward the pharmaceutical industry. Keeping this in mind, which of the stocks, SNDL Inc....
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.
The pharma industry’s prospects look bright, thanks to rising demand for innovative drugs. Thus, pharma stocks with potential upside, like GSK plc (GSK), Johnson & Johnson (JNJ), and Bristol-Myers Squibb...
The pharma industry’s prospects look bright, thanks to rising demand for generic and innovative drugs and technological advancements. Hence, adding fundamentally strong pharma stocks Astellas Pharma...
Moderna stock soared early in the pandemic.
Viatris, GSK, and Organon are all trading at less than 7 times earnings.
|Gsk Plc ADR|
|Vaneck Pharmaceutical ETF|
|Schwab International Dividend Equity ETF|
|Xt MSCI EAFE High Dividend Yield Equity ETF|
|Pacer Biothreat Strategy ETF|
|Horizon Kinetics Medical ETF|
|3rd Resistance Point||36.32|
|2nd Resistance Point||36.21|
|1st Resistance Point||36.07|
|1st Support Level||35.82|
|2nd Support Level||35.71|
|3rd Support Level||35.57|